<DOC>
	<DOCNO>NCT00612339</DOCNO>
	<brief_summary>Primary objective- To determine efficacy Avastin , 10 mg/kg every week , combination standard 5-day temozolomide term response rate . Secondary objective- To determine safety Avastin &amp; Temozolomide unresectable glioblastoma patient</brief_summary>
	<brief_title>Avastin Combination With Temozolomide Unresectable Multifocal GBMs Gliosarcomas</brief_title>
	<detailed_description>Subjects histologically confirm WHO gr IV primary malignant glioma unresectable/multifocal . This Phase II study 41 subject receive 4 cycle Avastin &amp; Temozolomide . Avastin administer 10 mg/kg every 14 day begin minimum 7 day biopsy/28 day craniotomy . Temozolomide dose 200 mg/m2 daily 5 day 28-day cycle . Patients receive 4 cycle Avastin &amp; Temozolomide , proceed standard XRT . Study use 2-stage `` minimax '' study design 21 subject accrue 1st stage , possibility additional 20 patient accrue 2nd stage . In initial Phase I &amp; II trial , 4 potential Avastin-associated safety signal identify : hypertension , proteinuria , thromboembolic event , &amp; hemorrhage . Avastin-associated adverse event Phase III trial include congestive heart failure , GI perforation , wound heal complication , &amp; arterial thromboembolic event . Most common toxicity associate Temozolomide mild myelosuppression .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients histologically confirm diagnosis WHO gr IV primary malignant glioma . Patients unresectable multifocal disease . Age ≥ 18years &amp; life expectancy &gt; 12 week Evidence measurable primary CNS neoplasm contrast enhance MRI . Interval &lt; 1 week prior biopsy/4 week surgical resection &amp; enrollment protocol Karnofsky ≥60 % Hemoglobin ≥9g/dl , ANC ≥1,500 cells/microliter , platelet ≥125,000 cells/microliter Serum creatinine ≤1.5 mg/dl , serum SGOT &amp; bilirubin ≤1.5 x ULN For patient corticosteroid , must stable dose 1 week prior entry , clinically possible , &amp; dose escalated entry dose level Signed inform consent approve IRB prior patient entry No evidence &gt; grade 1 CNS hemorrhage baseline MRI/CT scan If sexually active , patient take contraceptive measure duration treatment Pregnancy/breast feed Comedication may interfere study result Active infection require IV antibiotic Prior current Treatment w XRT/chemo brain tumor , irrespective grade tumor Evidence &gt; grade 1 CNS hemorrhage baseline MRI CT scan AvastinSpecific Concerns : Inadequately control hypertension Any prior history hypertensive crisis/hypertensive encephalopathy New York Heart Association Grade II &gt; congestive heart failure History myocardial infarction/unstable angina &lt; 6 month prior study enrollment History stroke/transient ischemic attack &lt; 6 month prior study enrollment Significant vascular disease Symptomatic peripheral vascular disease Evidence bleeding diathesis/coagulopathy Major surgical procedure , open biopsy , /significant traumatic injury within 28 day prior study enrollment/anticipation need major surgical procedure course study Core biopsy/other minor surgical procedure , exclude placement vascular access device , &lt; 7 day prior study enrollment History abdominal fistula , GI perforation , /intraabdominal abscess &lt; 6 month prior study enrollment Serious , nonhealing wound , ulcer , bone fracture Proteinuria screening demonstrate either UPC ratio ≥1.0 screening OR Urine dipstick proteinuria ≥2+ Known hypersensitivity component Avastin Pregnant/lactating . Use effective mean contraception subject childbearing potential Current , ongoing treatment fulldose warfarin equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>GBM</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Multifocal GBM</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Unresectable GBM</keyword>
	<keyword>Glioblastoma multiforme</keyword>
</DOC>